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http://dx
1326Background: Thoracic aortic aneurysms (TAAs) develop through an asymptomatic process resulting in gross
dilation that progresses to rupture if left undetected and untreated. If detected, patients with TAA are followed
over time until the risk of rupture outweighs the risk of surgical repair. Current methodologies for tracking TAA
size are limited to expensive computed tomography or magnetic resonance imaging because no acceptable popula-
tion screening tools are currently available. Previous studies from this laboratory and others have identified differ-
ential protein profiles for the matrix metalloproteinases (MMPs) and their endogenous tissue inhibitors (TIMPs), in
ascendingTAA tissue frompatientswith bicuspid aortic valves (BAVs), versus patientswith idiopathic degenerative
disease and a tricuspid aortic valve (TAV). In addition, altered microRNA (miR) expression levels have also been
reported in TAAs compared with normal aortic tissue. The objective of our study was to identify circulating factors
within plasma that could serve as potential biomarkers for distinguishing etiologic subtypes of aneurysm disease.
Methods: Ascending TAA tissue and plasma specimens were obtained from patients with BAV (n ¼ 21) and
TAV (n ¼ 21) at the time of surgical resection. The protein abundance of key MMPs (1, 2, 3, 8, and 9), TIMPs
(1, 2, 3, and 4), and miRs (1, 21, 29a, 133a, 143, and 145) was examined using a multianalyte protein profiling
system or by quantitative polymerase chain reaction, respectively. Results were compared with normal aortic
tissue and plasma obtained from patients without aortic disease (n ¼ 10).
Results: Significant (P<.05) differences in standardized miR-1 and miR-21 abundance between BAVand TAV
aortic tissue samples and different tissue and plasma profiles of analyte differences from normal aorta where
observed between the BAVand TAV groups. Linear regression analysis revealed significant linear relationships
in plasma and tissue measurements only for MMP-8 and TIMP-1, TIMP-3, and TIMP-4 (P<.05). Receiver
operator curve analysis revealed specific cassettes of analytes predictive of TAA disease. Relative to normal
aorta, BAV proteolytic balance was significantly increased for MMP-1, MMP-2, and MMP-7, and for decreased
MMP-8 and MMP-9. In contrast, TAV proteolytic balance relative to normal aorta was significantly increased
only for MMP-1 and decreased for MMP-8 and MMP-9.
Conclusions: Taken together, these unique data demonstrate differential plasma profiles of MMPs, TIMPs, and
miRs in ascending TAA specimens from patients with BAV and TAV. These results suggest that circulating
biomarkers may form the foundation for a broader platform of biomarkers capable of detecting the presence
of TAA using a simple blood test and may also be useful in personalized strategies to distinguish between
etiologic subtypes of TAAs in patients with aneurysm disease. (J Thorac Cardiovasc Surg 2013;145:1326-33)e Division of Cardiothoracic Surgery,a Department of Surgery, Medical
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The Journal of Thoracic and Cardiovascular SurThoracic aortic aneurysm (TAA) is an insidious and poten-
tially devastating disease process. Despite advancements in
our understanding of the pathobiology of TAAs, these find-
ings have yet to be translated into significant clinical appli-
cations for screening, diagnosis, tracking, and treatment
of TAAs.
From a biologic standpoint, numerous studies have con-
firmed that specific proteinases such as the matrix metallo-
proteinases (MMPs) and their endogenous inhibitors
(TIMPs) are implicated in the pathogenesis of ascending
TAAs.1-4 In addition, specific and different cassettes of
MMPs and TIMPs have been demonstrated in ascending
TAAs with different etiologies, such as those associated
with congenitally bicuspid aortic valves (BAVs) or
tricuspid aortic valves (TAVs).1-4 Similar findings havegery c May 2013
Abbreviations and Acronyms
AUC ¼ area under the curve
BAV ¼ bicuspid arterial valve
Ct ¼ cycle threshold
miR ¼ microRNA
MMP ¼ matrix metalloproteinase
MSA ¼ multiplex suspension array
TAA ¼ thoracic aortic aneurysm
TIMP ¼ tissue inhibitors of metalloproteinase
Ikonomidis et al Evolving Technology/Basic Sciencebeen demonstrated with microRNAs (miRs): different types
are seen to be expressed within these aneurysms.5 Many of
these agents can be reliably measured in plasma, providing
a potentially novel strategy to identify and follow the progres-
sion of TAAs. Accordingly, we sought to identify circulating
plasma factors associated with TAA that could distinguish
and predict the presence and etiologic subtype of aneurysm
disease.E
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Patient Demographics
Matched tissue and plasma specimens from 42 patients with ascending
aortic aneurysms (21 patients with BAV and 21 patients with TAV) were
taken from the widest region of the ascending aorta at the time of surgical
resection or aortic valve replacement. No patients had aortic dissection, in-
flammatory aortic disease, or known connective tissue disorder. Normal
aortic specimens were similarly harvested from the ascending aorta of heart
transplant donors or recipients (n ¼ 10). Mean  standard deviation ages
were 58  6 years in the normal group, 59  2 years in the BAV group,
and 70  2 years in the TAV group (TAV P<.05 from BAVand normal).
Seventy percent of normal group patients, 71% of BAV group patients, and
52% of TAV group patients were men. Aortic diameters were 3.8 0.2 cm
in the normal group, 5.2 0.2 cm in the BAV group, and 5.7 0.2 cm in the
TAV group (TAVand BAV P<.05 from normal). Normal aortic tissue and
plasma specimens were snap frozen and stored at 80C until analyzed.
This study was approved by the institutional review boards of the Medical
University of South Carolina, Duke University, and the University of Penn-
sylvania. Informed consent was obtained from all patients.
miR Isolation
Tissue samples. For each tissue sample, 5 mg frozen tissue was
weighed and homogenized using a bead-mill homogenizer (Qiagen,
Valencia, Calif). Total RNA was extracted from tissue homogenates
(mirVana PARIS miRNA Isolation kit; Applied Biosystems/Ambion,
Austin, Tex) and analyzed for RNA quality and quantity using an Expe-
rion Automated Electrophoresis System (RNA StdSens Analysis Kit;
Bio-Rad Laboratories, Hercules, Calif). Ten nanograms total RNA was
reversed transcribed (TaqMan MicroRNA Reverse Transcription Kit;
Applied Biosystems/Ambion, Austin, Tex) for each miR of interest, and
quantitative polymerase chain reaction (PCR) was performed. Each tissue
sample was analyzed for the following miRs: miR-1, miR-21, miR-29a,
miR-133a, miR-143, and miR-145. These were selected because previous
of previous findings by our group,5 their reported involvement in the reg-
ulation of specific protein targets within the cardiovascular system, in-
cluding several MMPs and extracellular matrix components (eg,
collagens, elastin, and microfibrillar proteins),6 and because of a previous
report of involvement (miR-143/miR-145) in ascending TAA formation.7The Journal of Thoracic and CarPlasma samples. RNA was isolated from 50 mL plasma (mirVana
PARIS Protein and RNA isolation System for Small RNAs; Ambion,
Austin, Tex) following the manufacturer’s instructions. The isolated
RNA (40 mL) was then incubated for 1 hour at room temperature with
1.3 units Heparinase-I (Ibex Pharmaceuticals Inc, Montreal, Quebec, Can-
ada) in a buffer containing 20 mM tris(hydroxymethyl)aminomethane (pH
7.5), 50 mM sodium chloride, 4 mM calcium chloride, and 0.01% bovine
serum albumin. Five microliters treated RNA was reverse transcribed for
each miR of interest and quantitative PCR was performed. Each plasma
sample was analyzed for the following miRs: miR-1, miR-21, miR-29a,
miR-133a, miR-143, and miR-145.
Quantitative PCR
For both tissue and plasma samples, the reverse transcription product
was amplified with gene-specific TaqMan primer/probe sets using the
TaqMan Universal PCR Master Mix with no AmperErase UNG (Catalog
No. 4324020; Applied Biosystems, Carlsbad, Calif) in a CFX96 Real-
Time PCR Detection System (Bio-Rad, Hercules, Calif). The thermal
cycling protocol was conducted as follows: 10 minutes at 95C, followed
by 40 cycles of 95C for 15 seconds, and 60C for 1 minute. Negative
PCR controls were run to verify the absence of genomic DNA contamina-
tion (no reverse transcription control). Fluorescence was recorded at regu-
lar intervals following the 60C annealing/extension segment of the PCR
reaction and real-time data showing relative fluorescence versus cycle
number was analyzed. Because of the paucity of good internal PCR con-
trols for plasma specimens, miR expression in both tissue and plasma
(for consistency of measurement) was determined from a change in cycle
threshold (DCt) value (expression ¼ 2(DCt)) where DCt was derived for
each individual specimen, and calculated by subtracting the mean Ct value
for all targets measured from the individual Ct value of a given PCR target,
as previously described.8,9 Results were then reported as a mean standard
error for each miR measured in either tissue or plasma.
MMP/TIMP Multiplex Suspension Array (MSA)
Utilizing an MSA approach, the tissue specimens were thawed and
transferred to a cold buffer (volume 1:6 w/v) containing 10 mM cacodylic
acid (pH 5.0), 0.15 M sodium chloride, 10 mM zinc chloride, 1.5 mM
sodium azide, and 0.01% Triton X-100 (v/v; Cat T8787, Sigma-Aldrich,
St Louis, Mo), and homogenized using a bead-mill homogenizer (Qiagen,
Valencia, Calif). The homogenates were then centrifuged (800 3 g, 10
minutes, 4C), and 20 mg protein was analyzed using an MSA approach.
MMPs 1, 2, 3, 7, 8, 9, 12, and 13 and TIMPs 1, 2, 3, and 4 were examined
as previously described.10 The plasma specimenswere analyzed in a similar
fashion following dilution (1:100 for MMP-2 and MMP-9; 1:10 for MMP-
1, MMP-3, MMP-7, MMP-8, MMP-12, and MMP-13; and 1:20 for the
TIMPs), as previously described.11 In both cases, samples were incubated
on a microplate shaker (room temperature, 2 hours), filtered, and washed 3
times with 100 mLwash buffer. Diluted goat antihuman polyclonal biotiny-
lated antibodies (50 mL, analyte specific [included with antibody-
conjugated bead kits]; R&D Systems, Inc, Minneapolis, Minn) were then
added to each well and the specimens were again incubated on a microplate
shaker (room temperature, 1 hour). The beads were filtered and washed as
before, and streptavidin-phycoerythrin (50 mL, R&D Systems, Inc) was
added to each well for 30 minutes at room temperature. After a final filtra-
tion and wash, the beads were analyzed using the Bio-Plex System; fluores-
cence was measured and then compared with standard curves for each
analyte also run on the same plate. Protein quantities were calculated using
Bio-Plex Manager Software (version 4.1) and expressed as absolute con-
centration in picograms per milliliter.
Data Analysis
Expression levels of miRs and protein abundance of the MMPs/TIMPs
were analyzed in 2 ways. First, all quantitative PCR and MSA results werediovascular Surgery c Volume 145, Number 5 1327
FIGURE 1. Aortic tissue and plasma analysis for microRNAs (miRs), matrix metalloproteinases (MMPs) and tissue inhibitors of matalloproteinases
(TIMPs), comparing ascending thoracic aortic aneurysms (TAAs) associated with bicuspid aortic valve (BAV) or tricuspid aortic valve (TAV) from normal
aortic samples (dashed line). Significant differences were observed between the BAVand TAV groups, and between the aneurysm groups and normal aorta
group. *P<.05 from normal aorta. yP<.05 from BAV.
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uted analytes, the absolute values were log transformed. Then all values
were subjected to a 1-way analysis of variance (prcomp module of Stata
version 8.2; Stata Corp, College Station, Tex) with Tukey’s wholly signif-
icant difference post hoc analysis for separation of means to determine dif-
ferences between the referent controls, BAV, and TAV groups. Second, the
percent change of miR and MMP/TIMP levels in the BAVand TAV groups
were computed and compared with the referent controls using a 1-sample
mean comparison test with the hypothesized mean set at 100%. Analysis of
variance with Tukey’s wholly significant difference post hoc analysis
(prcomp module) was used to determined differences between BAV and
TAV groups. Linear regression analysis was performed to identify signifi-
cant relationships between tissue and plasma levels of each analyte. In ad-
dition, plasma biomarkers were assessed for univariate association with the1328 The Journal of Thoracic and Cardiovascular Surpresence of aortic aneurysm using logistic regression models. Receiver op-
erating characteristic curves was then generated to compute an area under
the curve (AUC) for each individual biomarker. Biomarkers with P
values<.25 were considered for inclusion in a multiple logistic regression
model. Using forward stepwise variable selection, biomarkers were added
to the model with the variable most strongly associated with outcome (pres-
ence of a TAA) being added to the model until no more variables met the
entry criterion of a  0.20. The a level was set at 0.20 to ensure that even
marginally predictive biomarkers were captured. Logistic regression anal-
ysis was performed to determine the coefficients and intercepts for bio-
markers that were found to be significant predictors of aneurysm
development in multivariable analysis. Discrimination and classification
of the fitted multivariable models were assessed by using the generated
equation and computing the corresponding sensitivity, specificity, positivegery c May 2013
TABLE 1. Absolute values for microRNA (miR) expression and protein abundance of matrix metalloproteinases (MMPs) and tissue inhibitors of
metalloproteinase (TIMPs) in aortic tissue from healthy patients and patients with thoracic aortic aneurism (TAA) with bicuspid aortic valve (BAV)
or tricuspid aortic valve (TAV)
Tissue analyte Control BAV TAV
miR A (2DCt)
miR-1 (1 3 103) 57.8  2.4 54.3  3.3 39.4  3.3*,y
miR-21 (1 3 102) 169.7  21.4 217.7  32.3 683.0  191.0*,y
miR-29a (1 3 102) 242.4  33.3 274.7  17.2 220.2  25.8
miR-133a (1 3 103) 80.3  5.2 81.7  5.8 69.2  5.1
miR-143 (1 3 102) 830.9  37.9 703.7  45.9 560.6  49.1*
miR-145 (1 3 102) 771.0  37.9 910.8  72.1 715.0  75.6
MMPs (pg/mL)
MMP-1 3.4  1.0 15.7  4.0 11.3  2.8
MMP-2 (1 3 102) 71.6  13.0 64.1  7.7 56.9  5.4
MMP-3 292.9  45.5 165.2  22.4 160.6  20.2
MMP-7 (1 3 101) 8.8  2.9 14.6  3.8 24.0  7.2
MMP-8 (1 3 101) 294.1  128.8 121.7  29.3 128.5  49.8
MMP-9 (1 3 102) 74.9  49.6 28.3  7.1 26.0  7.9
MMP-12 ND ND ND
MMP-13 ND ND ND
TIMPs (pg/mL)
TIMP-1 (1 3 102) 113.6  13.7 100.2  5.9 111.3  6.1
TIMP-2 (1 3 102) 127.9  17.1 114.2  7.5 116.3  6.5
TIMP-3 (1 3 102) 22.2  3.0 16.5  1.5 18.8  2.2
TIMP-4 141.9  33.7 49.8  5.7* 43.6  4.6*
Sample size (n) 10 21 21
All analytes were subjected to a Shapiro-Wilk test for normality. For the unequally distributed analytes, the absolute values were log transformed and subjected to an 1-way
analysis of variance (prcompw module) with Tukey’s wholly significant difference post hoc analysis for separation of means to determine differences between the referent
controls, BAV, and TAV groups. ND, Not detectable. *P<.05 versus control. yP<.05 versus BAV.
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Spredictive, and negative predictive values.12 Finally, relative proteolytic
balance was expressed as the ratio of MMP abundance to a composite
TIMP score composed of the sum of TIMP-1, TIMP-2, TIMP-3, and
TIMP-4 abundance in each sample. Changes in the ratio of MMP abun-
dance to a composite TIMP score were determined by using a 1-sample
mean comparison test with the hypothesized mean for the referent controls
set at 100%. All statistical calculations were made using the Stata software
package version 8.2 (Stata Corp, College Station, Tex).E
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Tissue and plasma measurements of MMPs, TIMPs, and
miRs standardized to normal aorta or normal plasma are
shown in Figure 1. Absolute value measurements are sum-
marized in Table 1 (Tissue) and Table 2 (Plasma). There
were significant differences in the tissue and/or plasma
levels of several analytes with respect to control values.
Moreover, a differential expression of certain analytes
was observed in TAAs from the BAV and TAV groups.
For example, tissue levels of miR-1 and miR-21 were differ-
entially altered the TAV group compared with the BAV
group (Table 1) Lastly, relative proteolytic balance in the
tissue specimens was expressed as the ratio of MMP abun-
dance to a composite TIMP score composed of the sum of
TIMP-1, TIMP-2, TIMP-3, and TIMP-4 abundance in
each sample, as shown in Appendix Figure 1. Relative to
normal aorta, BAV proteolytic balance was significantly
increased for MMP-1, MMP-2, and MMP-7, and forThe Journal of Thoracic and Cardecreased MMP-8 and MMP-9. In contrast, TAV proteo-
lytic balance relative to normal aorta was significantly in-
creased only for MMP-1 and decreased for MMP-8 and
MMP-9.
Linear regression analysis, performed to identify signifi-
cant relationships between tissue and plasma levels of each
analyte, revealed significant linear relationships only for
MMP-8 and TIMP-1, TIMP-3, and TIMP-4. These results
are summarized in Figure 2.
Receiver operator characteristic curve analysis was per-
formed to determine if plasma levels of the analytes could
serve as biomarker(s) for the presence/absence of TAA dis-
ease. The AUC values from the univariate analysis are sum-
marized in Table 3. Following this, forward stepwise
multivariable receiver operating characteristics analysis
was performed, which revealed specific cassettes of analy-
tes predictive of TAA disease, as depicted in Figure 3. For
TAA disease overall, the combination of miR-143, MMP-
8, and miR-133a maximized AUC values to 0.9660. For
TAAs associated with BAV, the combination of MMP-2,
TIMP-2, miR-143, miR-133a, and miR-145 maximized
AUC values to 0.9766. For TAAs associated with TAV,
the combination of MMP-2, miR-143, and MMP-8 maxi-
mized AUC values to 0.9591.
Logistic regression coefficients and intercepts for bio-
markers that were found to be significant predictors ofdiovascular Surgery c Volume 145, Number 5 1329
TABLE 2. Absolute values for microRNA (miR) expression and protein abundance of matrix metalloproteinases (MMPs) and tissue inhibitors of
metalloproteinase (TIMPs) in plasma from patients with healthy aortae and patients with thoracic aortic aneurysm (TAA) with bicuspid aortic
valve (BAV) or tricuspid aortic valve (TAV)
Plasma analyte Control BAV TAV
miR (2-DCt)
miR-1 (1 3 103) 70.1  15.7 70.8  8.2 72.7  13.0
miR-21 42.5  11.7 36.7  5.8 32.4  5.6
miR-29a 7.2  1.4 6.1  0.7 5.7  0.8
miR-133a (1 3 103) 45.0  12.7 114.5  22.9 128.0  30.0
miR-143 (1 3 101) 14.4  2.5 12.2  1.4 11.3  1.4
miR-145 (1 3 102) 94.3  11.4 69.8  5.0 84.3  11.0
MMPs (pg/mL)
MMP-1 ND ND ND
MMP-2 (1 3 104) 53.4  4.7 45.6  3.6 41.9  3.1
MMP-3 (1 3 103) 22.8  3.6 16.1  2.9 19.7  4.6
MMP-7 (1 3 102) 20.8  18.4 16.0  6.3 35.5  14.5
MMP-8 (1 3 102) 91.0  28.9 13.3  3.5* 10.8  1.3*
MMP-9 (1 3 104) 83.6  21.5 25.6  3.5* 41.8  5.3*,y
MMP-12 ND ND ND
MMP-13 (1 3 102) 24.9  15.0 11.0  3.6 8.5  3.6
TIMPs (pg/mL)
TIMP-1 (1 3 103) 116.4  24.7 56.0  3.2* 63.8  7.2*
TIMP-2 (1 3 103) 55.2  2.8 43.6  1.7* 46.9  2.4
TIMP-3 (1 3 102) 34.2  4.6 24.1  2.8 36.2  4.6
TIMP-4 (1 3 102) 19.4  2.9 14.7  1.2 13.3  1.1
Sample size (n) 10 21 21
ND, Not detectable. *P<.05 versus control. yP<.05 versus BAV.
Evolving Technology/Basic Science Ikonomidis et al
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computed.
For all TAAs, the equation: Prob(control/aneur-
ysm) ¼ (2.771357 3 miR-143)  (0.0008061 3 MMP-8)
þ (50.81172 3 miR-133a)  3.615998 (r2, 0.59; P<.001)
yielded a positive predictive value of 0.92, a negative predic-
tive value of 0.58, a sensitivity of 0.87, and a specificity
of 0.70.
For the BAV group, the equation: Prob(control/aneur-
ysm) ¼ (0.0000152 3 MMP-2)  (0.0003459 3 TIMP-
2) þ (25.91564 3 miR-133a)  (8.569773 3 miR-145) þ
29.68998 (r2, 0.73; P<.001) resulted a positive predictive
value of 0.95, a negative predictive value of 1.00, a sensitivity
of 0.95, and a specificity of 1.00.
For the TAV group, the equation: Prob(control/aneur-
ysm) ¼ (0.0000284 3 MMP-2) þ (4.211116 3 miR-143)
 (0.0020155 3 MMP-8) þ 14.55217 (r2, 0.67; P< .001)
yielded a positive predictive value of 0.89, a negative predic-
tive value of 0.80, a sensitivity of 0.89, and a specificity
of 0.80.
DISCUSSION
Our knowledge of the pathobiology of TAAs continues to
expand and as such, it is becoming more apparent that this
information may be used to improve the way we diagnose,
track, and treat these serious conditions. Of particular sig-
nificance is that TAAs of different etiologic subtypes1330 The Journal of Thoracic and Cardiovascular Surdisplay different biologic patterns, which may allow for per-
sonalized health care strategies. Currently, TAAs are
diagnosed serendipitously during routine physical examina-
tions or assessments for other disease conditions. A screen-
ing test for TAAs would be very valuable to identify those
pateints who have asymptomatic but potentially life-
threatening aneurysms, necessitating knowledge of plasma
biomarker predictors. As such, this study undertook the task
of identifying plasma signatures that could be indicative of
specific subtypes of ascending aortic aneurysm disease.
This study demonstrated that it was possible to measure
a variety of different analytes directly relevant to TAA dis-
ease in plasma. Second, very little concordance between
plasma measurements and aortic tissue measurements of
MMPs, TIMPs, and a specific cassette of miRs was
observed. Third, it was shown that aneurysms associated
with either BAVs or TAVs displayed different cassettes of
tissue and plasma analytes. Finally, it was demonstrated
that it was possible to predict with a high degree of specific-
ity and sensitivity the presence of either aneurysm disease
in general or specific etiologic subtypes of aneurysm dis-
ease in particular using a plasma multianalyte regression
strategy. All of the above carries hope that such technology
could eventually be configured to a simple plasma measure-
ment that could aid with the screening of patients and per-
haps to use these signatures to predict aneurysm activity
or changes in aneurysm size.gery c May 2013
FIGURE 2. Linear regression analysis identifying significant relationships between analyte tissue and plasma levels. Significant relationships were found
for matrix metalloproteinase (MMP) 8, tissue inhibitor of metalloproteinase (TIMP) 1, TIMP-3, and TIMP-4.
Ikonomidis et al Evolving Technology/Basic ScienceIn our study, a significant number of MMPs, TIMPs, and
miRs were measured in aortic tissue. The results were con-
sistent to some extent with findings that we3,4 and others1,2TABLE 3. Area-under-the-curve (AUC) for individual plasma
analytes
All aneurysms BAV TAV
miR-1 0.4571 (.84) 0.4795 (.97) 0.4306 (.75)
miR-21 0.4538 (.46) 0.4850 (.65) 0.4211 (.37)
miR-29a 0.4077 (.31) 0.4300 (.41) 0.3842 (0.35)
miR-133a 0.7654 (<.01)* 0.7602 (<.01)* 0.7712 (<.01)*
miR-143 0.3596 (.23) 0.3567 (.36) 0.3626 (.21)
miR-145 0.3385 (.21) 0.2700 (.02)* 0.4105 (.65)
MMP-1 ND
MMP-2 0.2615 (.03)* 0.3050 (.07) 0.2158 (.02)*
MMP-3 0.3231 (.45) 0.3350 (.28) 0.3105 (.62)
MMP-7 0.6071 (.80) 0.5769 (.66) 0.6333 (.56)
MMP-8 0.1321 (<.01)* 0.1275 (<.01)* 0.1368 (<.01)*
MMP-9 0.1667 (<.01)* 0.0950 (<.01)* 0.2421 (<.01)*
MMP-12 ND
MMP-13 0.3590 (.08) 0.3889 (.20) 0.3333 (.10)
TIMP-1 0.2231 (<.01)* 0.1850 (<.01)* 0.2632 (<.01)*
TIMP-2 0.2051 (<.01)* 0.1300 (<.01)* 0.2842 (.03)*
TIMP-3 0.3833 (.44) 0.2575 (.04)* 0.5158 (.75)
TIMP-4 0.3205 (.04)* 0.3650 (.18) 0.2737 (.01)*
Values are presented as AUC (P value) for each individual analyte. BAV,Bicuspid aor-
tic valve; TAV, tricuspid aortic valve; miR, microRNA; MMP, matrix metalloprotei-
nase; ND, not detectable; TIMP, tissue inhibitor of metalloproteinase. *AUC value
is statistically significant in univariate analysis.
The Journal of Thoracic and Car
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these analytes for aneurysms of different etiologies. This
data further supports the concept that different etiologic
subtypes of TAAs display measurable biologic differences
that can be used to distinguish meaningfully between
these disease processes.
We showed that a broad range of analytes could be mea-
sured in the plasma and that it was possible to generate a dif-
ferent cassette of specific analyte profiles for TAAs
associated with BAV or TAV. What was interesting with
this study was that in general it was not possible to demon-
strate a specific correlation between most tissue and plasma
analyte levels. The reasons for this are multifactorial and in-
clude the fact that many of the biomarkers measured are pri-
marily interstitial molecules and hence it may be difficult to
predict how much measurable spillage into plasma would
be observed or expected. Furthermore, the half-life of the
analytes is variable, making it difficult to correlate plasma
and tissue concentrations. Also, tissue and plasma storage
and handling affects the ability to accurately measure ana-
lytes. Although handling of tissue and plasma is an impor-
tant and rigorous procedure in the laboratory, it is possible
that aberrancies in the storage and processing may have af-
fected the results and decreased the degree of concordance
between tissue and plasma levels.
Previous work has underscored the potential for using
plasma analytes to predict aortic disease and the results ofdiovascular Surgery c Volume 145, Number 5 1331
FIGURE 3. Receiver operating characteristic curves to assess plasma an-
eurysm predictability. Inclusion of plasma analytes using forward stepwise
variable selection resulted in different combinations for thoracic aortic an-
eurism (TAA) in general (top), bicuspid aortic valve-associated TAAs (mid-
dle), and tricuspid aortic valve-associated TAAs (bottom) providing high
area-under-the curve (AUC) values, indicating high sensitivity and specific-
ity. MMP, Matrix metalloproteinase; TIMP, tissue inhibitor of metallopro-
teinase; miR, microRNA.
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MMPs, C-reactive protein, and D-dimer, have shown prom-
ise in the prediction of acute aortic dissection.13 A recent
meta-analysis implicated measurement of circulating
MMP-9 as an indicator of abdominal aortic aneurysm dis-
ease,14 and plasma measurement of MMP-1 and MMP-9
has been shown to be predictive of aortic rupture.15 Further,1332 The Journal of Thoracic and Cardiovascular Surcomposite measurement of high-density lipoprotein,
C-reactive protein, and immunoglobulin G correlates to
abdominal aortic aneurysm size.16 In the thoracic aorta,
measurement of circulating MMP-9 has been shown to cor-
relate to aortic root dilation.17 Interestingly, elevated
plasma MMP-9 levels have been used to predict endoleaks
after endovascular therapy of the abdominal18 and tho-
racic19 aorta. Our work supports the above results and estab-
lishes preliminary algorithms for the screening of patients
for ascending aortic aneurysm disease.
An important finding in our study is that measurement
of single analytes is not predictive of aneurysm disease to
any significant level, but a stepwise combination of mul-
tiple analytes produces an algorithm that is highly sensi-
tive and specific. As discussed above, a similar trend
has been observed for predictions of aortic dissection
and abdominal aortic aneurysm.13,16 Hence, aneurysms
of different etiologies could have specific plasma
regression equations containing a composite of analytes
that would accurately predict the presence of disease
as a screening tool in patients before referral for
confirmatory imaging.
It must be understood that this study has significant lim-
itations. The sample size of measurement is relatively
small and also the panel of MMPs, TIMPs, and miRs
tested, although significant in size, is not comprehensive.
Further studies must be undertaken testing a larger bank
of analytes to assess for any further significance. In addi-
tion, it must be realized that the regression equations gen-
erated for different aneurysm subtypes must be tested in
a larger bioset for validation. Related to this, postresection
plasma samples would be important for validation of the
biomarker algorithm. As already discussed, the results of
the study may be limited by issues related to obtaining,
storing, and processing of tissue and plasma within a mul-
ticenter biobank such as the aortic biobank housed at the
Medical University of South Carolina. Further refinement
of storage protocols and processing should decrease the
variability associated with measurements. Because the aor-
tic tissue was snap-frozen and analyzed following homog-
enization, differentiation of biomarker elaboration between
cell types was not possible. This latter point is a challeng-
ing area, because in addition to release of biomarkers from
cells that have undergone apoptosis, some analytes such as
miRs are actively and selectively exported by living
cells,20 thus significantly confounding the cellular origin
issue. Lastly, this observational study does not offer any
significant insight regarding which tissue and/or circulat-
ing biomarker is a predictor of aortic growth and/or rupture
and/or dissection.
The above limitations notwithstanding, the results of this
study indicate that specific plasma biosignatures can be
generated for aneurysms of different subtypes. These data
hold significant importance with regard to the potentialgery c May 2013
Ikonomidis et al Evolving Technology/Basic Scienceadvancement of diagnosis, tracking, and treatment of tho-
racic aortic aneurysm disease.References
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